Literature DB >> 33906942

Genetic removal of p70 S6K1 corrects coding sequence length-dependent alterations in mRNA translation in fragile X syndrome mice.

Sameer Aryal1,2, Francesco Longo2, Eric Klann3,4.   

Abstract

Loss of the fragile X mental retardation protein (FMRP) causes fragile X syndrome (FXS). FMRP is widely thought to repress protein synthesis, but its translational targets and modes of control remain in dispute. We previously showed that genetic removal of p70 S6 kinase 1 (S6K1) corrects altered protein synthesis as well as synaptic and behavioral phenotypes in FXS mice. In this study, we examined the gene specificity of altered messenger RNA (mRNA) translation in FXS and the mechanism of rescue with genetic reduction of S6K1 by carrying out ribosome profiling and RNA sequencing on cortical lysates from wild-type, FXS, S6K1 knockout, and double knockout mice. We observed reduced ribosome footprint (RF) abundance in the majority of differentially translated genes in the cortices of FXS mice. We used molecular assays to discover evidence that the reduction in RF abundance reflects an increased rate of ribosome translocation, which is captured as a decrease in the number of translating ribosomes at steady state and is normalized by inhibition of S6K1. We also found that genetic removal of S6K1 prevented a positive-to-negative gradation of alterations in translation efficiencies (RF/mRNA) with coding sequence length across mRNAs in FXS mouse cortices. Our findings reveal the identities of dysregulated mRNAs and a molecular mechanism by which reduction of S6K1 prevents altered translation in FXS.

Entities:  

Keywords:  autism; fragile X syndrome; mRNA translation; protein synthesis; translation elongation

Mesh:

Substances:

Year:  2021        PMID: 33906942      PMCID: PMC8106352          DOI: 10.1073/pnas.2001681118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Genome-wide analysis of mRNA translation profiles in Saccharomyces cerevisiae.

Authors:  Yoav Arava; Yulei Wang; John D Storey; Chih Long Liu; Patrick O Brown; Daniel Herschlag
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-26       Impact factor: 11.205

2.  Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse.

Authors:  Mei Qin; Julia Kang; Thomas V Burlin; Chunhui Jiang; Carolyn Beebe Smith
Journal:  J Neurosci       Date:  2005-05-18       Impact factor: 6.167

3.  Expression of fragile X mental retardation protein in neurons and glia of the developing and adult mouse brain.

Authors:  Shervin Gholizadeh; Sebok Kumar Halder; David R Hampson
Journal:  Brain Res       Date:  2014-11-20       Impact factor: 3.252

4.  Dysregulation of mTOR signaling in fragile X syndrome.

Authors:  Ali Sharma; Charles A Hoeffer; Yukihiro Takayasu; Takahiro Miyawaki; Sean M McBride; Eric Klann; R Suzanne Zukin
Journal:  J Neurosci       Date:  2010-01-13       Impact factor: 6.167

5.  Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program.

Authors:  C Chauvin; V Koka; A Nouschi; V Mieulet; C Hoareau-Aveilla; A Dreazen; N Cagnard; W Carpentier; T Kiss; O Meyuhas; M Pende
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

6.  SKAR is a specific target of S6 kinase 1 in cell growth control.

Authors:  Celeste J Richardson; Mark Bröenstrup; Diane C Fingar; Kristina Jülich; Bryan A Ballif; Steven Gygi; John Blenis
Journal:  Curr Biol       Date:  2004-09-07       Impact factor: 10.834

7.  mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF.

Authors:  Katherine M Hannan; Yves Brandenburger; Anna Jenkins; Kerith Sharkey; Alice Cavanaugh; Lawrence Rothblum; Tom Moss; Gretchen Poortinga; Grant A McArthur; Richard B Pearson; Ross D Hannan
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

8.  The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes.

Authors:  Lucia Lisi; Pierluigi Navarra; Douglas L Feinstein; Cinzia Dello Russo
Journal:  J Neuroinflammation       Date:  2011-01-05       Impact factor: 8.322

9.  Integrative analysis of RNA, translation, and protein levels reveals distinct regulatory variation across humans.

Authors:  Can Cenik; Elif Sarinay Cenik; Gun W Byeon; Fabian Grubert; Sophie I Candille; Damek Spacek; Bilal Alsallakh; Hagen Tilgner; Carlos L Araya; Hua Tang; Emiliano Ricci; Michael P Snyder
Journal:  Genome Res       Date:  2015-08-21       Impact factor: 9.043

10.  Cell Type-Specific mRNA Dysregulation in Hippocampal CA1 Pyramidal Neurons of the Fragile X Syndrome Mouse Model.

Authors:  Laura Ceolin; Nathalie Bouquier; Jihane Vitre-Boubaker; Stéphanie Rialle; Dany Severac; Emmanuel Valjent; Julie Perroy; Emma Puighermanal
Journal:  Front Mol Neurosci       Date:  2017-10-20       Impact factor: 5.639

View more
  4 in total

1.  A deep dive into local mRNA translation in neurons.

Authors:  Mauricio M Oliveira; Eric Klann
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-09       Impact factor: 11.205

2.  Excess ribosomal protein production unbalances translation in a model of Fragile X Syndrome.

Authors:  Sang S Seo; Susana R Louros; Natasha Anstey; Miguel A Gonzalez-Lozano; Callista B Harper; Nicholas C Verity; Owen Dando; Sophie R Thomson; Jennifer C Darnell; Peter C Kind; Ka Wan Li; Emily K Osterweil
Journal:  Nat Commun       Date:  2022-06-10       Impact factor: 17.694

Review 3.  eIF2-dependent translation initiation: Memory consolidation and disruption in Alzheimer's disease.

Authors:  Mauricio M Oliveira; Eric Klann
Journal:  Semin Cell Dev Biol       Date:  2021-07-23       Impact factor: 7.727

4.  FMRP-dependent production of large dosage-sensitive proteins is highly conserved.

Authors:  Keegan Flanagan; Alireza Baradaran-Heravi; Qi Yin; Khanh Dao Duc; Allan C Spradling; Ethan J Greenblatt
Journal:  Genetics       Date:  2022-07-30       Impact factor: 4.402

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.